Candel Therapeutics Financial Ratios Analysis
Valuation, profitability, leverage, and liquidity ratios
| Breakdown | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
| Valuation Ratios | ||||||
| P/S Ratio | - | - | - | 413.76 | 1794.84 | - |
| P/B Ratio | 5.97 | 5.56 | 3.34 | 1.08 | 3.50 | - |
| Price/Tangible Book | 5.97 | 5.56 | 3.34 | 1.08 | 3.50 | - |
| Enterprise Value Ratios | ||||||
| EV/Revenue | - | - | - | - | 1092.09 | - |
| Profitability & Returns | ||||||
| Return on Equity (ROE) | −64.58% | −139.56% | −125.50% | −33.60% | −80.60% | −53.16% |
| Return on Assets (ROA) | −25.95% | −28.14% | −39.95% | −26.01% | −25.22% | −20.51% |
| Return on Capital Employed (ROCE) | −41.50% | −48.10% | −140.70% | −48.20% | −30.70% | −41.10% |
| Leverage & Solvency Ratios | ||||||
| Debt/Equity | 0.94 | 0.20 | 1.79 | 0.48 | 0.01 | 0.04 |
| Liquidity Ratios | ||||||
| Current Ratio | 13.49 | 2.77 | 2.59 | 12.81 | 15.84 | 7.46 |
| Quick Ratio | 13.31 | 2.73 | 2.50 | 12.48 | 15.41 | 7.44 |
| Efficiency Ratios | ||||||
| Asset Turnover | - | - | - | 0.00 | 0.00 | 0.00 |
| Yield & Distribution Ratios | ||||||
| Earnings Yield | −12.31% | −14.97% | −89.24% | −36.34% | −16.10% | - |
| FCF Yield | −12.54% | −7.33% | −81.63% | −63.26% | −10.72% | - |
| Buyback Yield | −67.19% | −9.47% | −0.39% | −52.72% | −62.49% | −0.70% |
Source: Company financial statements from annual and quarterly filings. Data as of Sep 30, 2026. Data sources and methodology
